Monotherapy superior to placebo | Monotherapy at least comparable to MTX/DMARDs | Monotherapy at least comparable to the agent plus MTX/DMARDs | |
---|---|---|---|
TNFi agents | |||
Adalimumab | ✓100 | ✓14 | X14 15 101 |
Etanercept | NR | ✓3 17 102 103 104 | ✓102 107 X3 17 40 41 105 |
Golimumab | ✓128 129 | ✓16 108 109 | X16 |
Certolizumab | ✓21 110 | NR | NR |
Non-TNFi agents | |||
Abatacept | ✓111 | NR | ✓112 |
Rituximab | NR | ✓22 | NR |
Anakinra | ✓113 | NR | NR |
Tocilizumab | ✓117 | ✓114 115 117 125 130 | ✓79 119 120 122 131 |
Tofacitinib | NR | ✓132 | NR |
DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; NR, not reported; TNFi, tumour necrosis factor inhibitor.